MaxCyte has entered an agreement to acquire Akron Bio for $151.8 million, a deal expected to nearly double its revenue base and expand its cell therapy manufacturing business.
The transaction, announced Nov. 10, is expected to close before the end of 2026, subject to customary closing conditions.
Akron supplies materials used in cell therapy manufacturing, including cytokines, growth factors and human plasma-derived products. The acquisition will expand MaxCyte’s presence across viral and nonviral cell therapy production, with the combined portfolio supporting five commercially approved therapies and more than 100 clinical programs.
Akron is projected to generate approximately $28 million in revenue and $7 million to $8 million in earnings before interest, taxes, depreciation and amortization in 2026. MaxCyte expects the acquisition to increase recurring revenue and reduce the combined company’s annual cash burn to less than $10 million in 2027.
Under the agreement, MaxCyte will pay $105 million in cash, issue approximately $26.8 million in stock and make $20 million in deferred payments. The company also secured a credit facility of up to $75 million from MidCap Financial, which it expects, together with cash on hand, to fund operations through profitability.
Akron is expected to continue operating under its existing brand.
